This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quan, S.
Right arrow Articles by Furihata, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quan, S.
Right arrow Articles by Furihata, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1999, p. 181-184, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

ADP-Ribosylation as an Intermediate Step in Inactivation of Rifampin by a Mycobacterial Gene

Selwyn Quan,1 Tamae Imai,2 Yuzuru Mikami,2,* Katsukiyo Yazawa,2 Eric R. Dabbs,1 Naoko Morisaki,3 Shigeo Iwasaki,3,dagger Yuichi Hashimoto,3 and Kazuo Furihata4

Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, Chuo-ku, Chiba 260-8673,2 Institute of Molecular and Cellular Biosciences3 and Department of Agricultural Chemistry,4 University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113, Japan, and Genetics Department, University of the Witwatersrand, Johannesburg 2050, South Africa1

Received 9 March 1998/Returned for modification 20 October 1998/Accepted 4 November 1998

Mycobacterium smegmatis DSM43756 inactivates rifampin, and the inactivated antibiotic product recovered from culture medium was ribosylated on the 23-OH group. To study this process, the gene responsible for the inactivation was expressed at high levels by the lac promoter in Escherichia coli conferring resistance to >500 µg of antibiotic per ml. Cell homogenates generated a novel derivative designated RIP-TAs; in this study, we determined that RIP-TAs is 23-(O-ADP-ribosyl)rifampin. Our results indicated that RIP-TAs is an intermediate in the pathway leading to ribosylated rifampin and that the previously characterized gene encodes a mono(ADP-ribosyl)transferase which, however, shows no sequence similarity to other enzymes of this class.

* Corresponding author. Mailing address: Research Center for Pathogenic Fungi and Microbial Toxicoses, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8673, Japan. Phone: 81-43-222-7171, ext. 5923. Fax: 81-43-226-2486. E-mail: mikami{at}myco.pf.chiba-u.ac.jp.

dagger Present address: The Kitasato Institute, 5-9-1, Shirokane, Minato-ku, Tokyo 108, Japan.

Antimicrobial Agents and Chemotherapy, January 1999, p. 181-184, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Baysarowich, J., Koteva, K., Hughes, D. W., Ejim, L., Griffiths, E., Zhang, K., Junop, M., Wright, G. D. (2008). Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr. Proc. Natl. Acad. Sci. USA 105: 4886-4891 [Abstract] [Full Text]  
  • Alexander, D. C., Jones, J. R. W., Liu, J. (2003). A Rifampin-Hypersensitive Mutant Reveals Differences between Strains of Mycobacterium smegmatis and Presence of a Novel Transposon, IS1623. Antimicrob. Agents Chemother. 47: 3208-3213 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»